Clinical Trials

Clinical Trials

SRF231

SRF231 is an investigational monoclonal antibody that inhibits the activity of CD47, a cell surface protein which plays an important role in allowing tumor cells to escape destruction by a particular type of immune cell called a macrophage.

Surface has initiated a Phase 1 clinical trial which is currently evaluating the safety and tolerability of SRF231 in multiple ascending doses with the goal of establishing a recommended dose for further study as monotherapy in patients with specific solid and hematologic malignancies. Subsequently, and depending upon the results of our earlier trial data, we intend to evaluate the safety and efficacy of SRF231 in combination with other cancer therapies in patients.

Compassionate Use Statement